William Blair Raises Earnings Estimates for Krystal Biotech

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at William Blair lifted their Q1 2025 earnings estimates for shares of Krystal Biotech in a note issued to investors on Wednesday, February 19th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of $1.47 for the quarter, up from their previous forecast of $1.25. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share. William Blair also issued estimates for Krystal Biotech’s Q2 2025 earnings at $1.64 EPS, Q3 2025 earnings at $1.82 EPS, Q4 2025 earnings at $2.11 EPS, FY2025 earnings at $7.04 EPS and FY2026 earnings at $9.97 EPS.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The business’s quarterly revenue was up 116.4% on a year-over-year basis. During the same period last year, the business earned $0.30 EPS.

Several other equities analysts have also recently weighed in on KRYS. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 target price on shares of Krystal Biotech in a research note on Thursday, February 20th. Chardan Capital raised their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday, February 19th. Finally, Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Trading Down 3.1 %

NASDAQ:KRYS opened at $181.10 on Monday. Krystal Biotech has a 1-year low of $125.85 and a 1-year high of $219.34. The firm has a fifty day simple moving average of $158.24 and a 200 day simple moving average of $175.31. The stock has a market capitalization of $5.22 billion, a PE ratio of 60.57 and a beta of 0.84.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds have recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the 3rd quarter valued at $40,000. Huntington National Bank lifted its holdings in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company’s stock worth $104,000 after buying an additional 283 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company’s stock worth $107,000 after buying an additional 412 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech during the fourth quarter worth $95,000. Finally, KBC Group NV lifted its holdings in shares of Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after buying an additional 132 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).